Canadian application, no grantCanada
Aspergillus foetidus expression system
CA 2178008 A1 · Owner: Novo Nordisk Biotech, Inc. · Inventors: Takagi, Shinobu; Berka, Randy M.; Boominathan, Karuppan Chettier
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a novel expression system in which Aspergillus foetidus host cells are used to express heterologous enzymes.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 29, 1994. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 29, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 29, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledNovember 29, 1994
GrantedNo grant recorded
Term endedNovember 29, 2014
Patent numberCA 2178008 A1
Classification (IPC)C12N15/80 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.